Dartmouth-Hitchcock Medical Center
Scott C. Jaynes
The primary objective of this study is to demonstrate the feasibility of evaluating SAMe tolerability, analgesic benefits, and daily functional improvement in patients with osteoarthritis of the hands compared to placebo. The secondary objective of this study is to generate preliminary data on discomfort, function, quality of life in patients with osteoarthritis of the hands when taking SAMe compared to placebo.
Osteoarthritis Hand
S-Adenosyl-L-Methionine (Sam-E)
Placebo
Phase 4
At week 0, all patients giving written informed consent and meeting eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to SAMe (400mg orally, twice daily) or placebo (400mg, twice daily) for 8 weeks. Followed by a one week wash out period followed by another 8 weeks of SAMe (400mg, twice daily) or placebo (400mg, twice daily) for 8 weeks (whichever was not given during the first 8 week period). Participants will complete weekly surveys during the entire study regarding hand discomfort, functional limitations and side effects}}
Study Type : | Interventional |
Estimated Enrollment : | 40 participants |
Masking : | Triple |
Primary Purpose : | Supportive Care |
Official Title : | S-Adenosyl-L-Methionine (SAMe) vs Placebo for Discomfort and Functional Limitations Associated With Osteoarthritis of the Hands: a Pilot Study |
Actual Study Start Date : | August 17, 2022 |
Estimated Primary Completion Date : | May 1, 2024 |
Estimated Study Completion Date : | August 1, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: S-Adenosyl-L-Methionine (SAMe) Participants receive S-Adenosyl-L-Methionine (SAMe) 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period. |
Drug: S-Adenosyl-L-Methionine (Sam-E) Drug: Placebo |
Placebo Comparator: Placebo Participants receive identically appearing 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period. |
Drug: S-Adenosyl-L-Methionine (Sam-E) Drug: Placebo |
Ages Eligible for Study: | 40 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756